Race's first important asset is a chemotherapy drug called Bisantrene which was the subject of more than 40 phase II clinical studies before it was lost in a series of pharmaceutical mergers during the 1990s. Race Oncology has rediscovered Bisantrene and we plan to put this valuable drug back in the hands of clinicians to treat Leukaemia.
In the United States, Race owns two granted patents on Bisantrene and has secured Orphan Drug designation and Rare Paediatric Disease designation. Our goal is to complete clinical development and gain approval by the US FDA.
Race Oncology CEO Peter Molloy and Chair Dr Bill Garner.
Race Oncology has announced the US Food and Drug Administration has received its
Race Oncology is pleased to announce that Dr Roland Walter has agreed to be the Principal
Race Oncology is pleased to announce that it has executed a consulting agreement with Professor
Race Oncology is very pleased to announce that it has executed a Named Patient Program (NPP)
Race Oncology is pleased to announce it has executed a services agreement with BioSynergy
A new report by Independent Investment Research suggests that Australian biotech Race Oncology